bologna - ER Congressi

PROGRAM
President:
Pier Luigi Zinzani
Co-President: Michele Cavo
Honorary President: Sante Tura
Bologna,
Royal Hotel Carlton
May 9-11, 2016
BOLOGNA
BOLOGNA, ROYAL HOTEL CARLTON
Under the Auspices of
UNIVERSITÀ DEGLI STUDI DI BOLOGNA
REGIONE EMILIA-ROMAGNA
AZIENDA OSPEDALIERO-UNIVERSITARIA
DI BOLOGNA
AIL ASSOCIAZIONE ITALIANA CONTRO
LE LEUCEMIE - LINFOMI E MIELOMA
SEZIONE DI BOLOGNA
SIE - SOCIETÀ ITALIANA DI EMATOLOGIA
Faculty
SergioAmadori
MicheleBaccarani
GiovanniBarosi
Peter Tim H.
Pier Luigi
Borchmann
Canonico
FranciscoCervantes
Cheson
PaoloCorradini
Steven E.
Coutre
AntonioCuneo
Sven
de Vos
HartmutDohner
MartinDreyling
RobinFoà
Nathan H.
Fowler
ArmandoGenazzani
MarcoGobbi
Hans C.
Bologna, Italy
Pavia, Italy
Cologne, Germany
Brummendorf Aachen, Germany
MicheleCavo
Bruce D.
Roma, Italy
Hasselbalch
PeterHillmen
BrianHuntly
Novara, Italy
Bologna, Italy
Barcelona, Spain
Washington, USA
Milano, Italy
Stanford, USA
Ferrara, Italy
Los Angeles, USA
Ulm, Germany
München, Germany
Roma, Italy
Houston, USA
Novara, Italy
Genova, Italy
Copenhagen, Denmark
Leeds, United Kingdom
June
HagopKantarjian
ArneKolstad
ShajiKumar
StevenLeGouill
SagarLonial
MaurizioMartelli
GiovanniMartinelli
AnthonyMato
Ruben A.
Mesa
FrankMorschhauser
Lille, France
Alison J.
Owen A.
Susan M.
Moskowitz
O’Connor
O’Brien
MichinoriOgura
FabrizioPane
Nantes, France
Nantes, France
Roma, Italy
Bologna, Italy
Philadelphia, USA
Scottsdale, USA
Gifu, Japan
Napoli, Italy
RuthPettengell
London, United Kingdom
AntonelloPinto
PierluigiPorcu
Napoli, Italy
Columbus, USA
VincentRibrag Villejuif, France
Paul G.
Richardson
GianantonioRosti
SimonRule
GiuseppeSaglio
Boston, USA
Bologna, Italy
Plymouth, United Kingdom
Torino, Italy
StephenSchuster Philadelphia, USA
Laurie H.
Sehn
Vancouver, Canada
SharonShacham
Newton, USA
Eytan M.
Rochester, USA
Irvine, USA
MaltePetersBasel, Switzerland
Philadelphia, USA
Oslo, Norway
New York, USA
FrancescoPassamontiVarese, Italy
MicheleSpina
Houston, USA
New York, USA
AntonioPalumboTorino, Italy
Cambridge, United Kingdom
IlariaIacobucci
Memphis, USA
Carl H.
PhilippeMoreau Nantes, France
AnastasiosStathis
Richard M.
Stein
Stone
Aviano - PN, Italy
Bellinzona, Switzerland
New York, USA
Boston, USA
AronThall San Diego, USA
Max S.
Alessandro M.
Topp
Vannucchi
UmbertoVitolo
MichaelWang
Thomas E.
Witzig
Pier Luigi
Zinzani
Würzburg, Germany
Firenze, Italy
Torino, Italy
Houston, USA
Rochester, USA
AnasYounes
New York, USA
Bologna, Italy
1
Monday, May 9, 2016
9.00 a.m.
Welcome and Introduction
Three recent “impressive” stories
Chairman: F. Pane
9.15 a.m.
9.45 a.m.
10.15 a.m.
Brentuximab Vedotin in lymphomas - A. Younes
Blinatumumab in ALL - M.S. Topp
CAR T-cells - C.H. June
10.45 a.m.
Coffee Break
Session I: Classical Ph1-neg myeloproliferative neoplasms
Chairmen: F. Passamonti, A.M. Vannucchi
2
11.00 a.m.
11.25 a.m.
Status of the art of treatment - R.A. Mesa
11.40 a.m.
11.55 a.m.
12.10 p.m.
12.25 p.m.
Ruxolitinib in myelofibrosis - F. Passamonti
Ruxolitinib in polycitemia vera - A.M. Vannucchi
New JAK2 inhibitors in MPNs and combination therapy - F. Cervantes
Interferons in MPNs - H.C. Hasselbalch
Newer drugs for myelofibrosis - G. Barosi
12.40 p.m.
Lunch
Session II: Hodgkin’s lymphoma
Chairmen: P. Borchmann, P.L. Zinzani
1.45 p.m.
2.10 p.m.
2.25 p.m.
2.40 p.m.
2.55 p.m.
Status of the art of treatment - P. Borchmann
Nivolumab - A. Younes
Pembrolizumab - S. Schuster
Bendamustine - A.J. Moskowitz
New Combo-steps - A. Younes
Session III: Chronic myeloid leukemia
Chairmen: M. Gobbi, G. Rosti
3.30 p.m.
3.55 p.m.
4.15 p.m.
4.30 p.m.
4.45 p.m.
Status of the art of treatment - M. Baccarani
Nilotinib-based treatments and ABL001 - G. Rosti
Dasatinib and combination - G. Saglio
Bosutinib - T.H. Brummendorf
Ponatinib - G. Rosti
3
Tuesday, May 10, 2016
Two “transversal on lymphomas” drugs
Chairman: P. Corradini
8.30 a.m.
9.00 a.m.
Bendamustine - B.D. Cheson
Lenalidomide - T.E. Witzig
Session IV: Non-Hodgkin’s lymphoma (I)
Chairmen: B.D. Cheson, A. Pinto
4
9.15 a.m.
9.40 a.m.
9.55 a.m.
10.10 a.m.
10.25 a.m.
10.40 a.m.
Status of the art of treatment - B.D. Cheson
Obinutuzumab - L.H. Sehn
Ublituximab - N.H. Fowler
MOR208 - P.L. Zinzani
anti-4-1BB - A. Thall
10.55 a.m.
11.15 a.m.
11.30 a.m.
11.45 a.m.
12.00 p.m.
12.15 p.m.
12.45 p.m.
Polatuzumab - F. Morschhauser
Mogamulizumab - M. Ogura
177Lu-HH1 (Betalutin) - A. Kolstad
CC-122 - V. Ribrag
EDO-S101 - O.A. O’Connor
IMGN529 - A. Stathis
Selinexor - S. Shacham
Pixantrone - R. Pettengell
1.00 p.m.
Lunch
Session V: Non-Hodgkin’s lymphoma (II)
Chairmen: M. Martelli, U. Vitolo
2.00 p.m.
2.15 p.m.
2.30 p.m.
2.45 p.m.
3.00 p.m.
3.15 p.m.
3.30 p.m.
3.45 p.m.
Venetoclax - S. Rule
Idelalisib - S. de Vos
Ibrutinib - M. Wang
TGR-1202 - O.A. O’Connor
Copanlisib - M. Dreyling
Duvelisib - N.H. Fowler
Acalabrutinib - S. LeGouill
Tazemetostat - V. Ribrag
Session VI: Chronic Lymphocitic Leukemia
Chairmen: A. Cuneo, R. Foà
4.15 p.m.
4.45 p.m.
5.00 p.m.
5.15 p.m.
5.30 p.m.
5.45 p.m.
6.00 p.m.
Status of the art of management - S.M. O’Brien
Ibrutinib - P. Hillmen
Idelalisib - S.E. Coutre
Venetoclax - P. Hillmen
Acalabrutinib - S.M. O’Brien
Duvelisib - P. Porcu
TGR-1202 and Ublituximab - A. Mato
5
Wednesday, May 11, 2016
Session VII: Multiple myeloma
Chairmen: M. Cavo, S. Lonial
8.30 a.m. Status of the art of treatment - A. Palumbo
8.55 a.m. Modelling of disease evolution: what have we learned and
how can we drive future treatment strategies? - P.G. Richardson
9.10 a.m. Immune checkpoint inhibitors and immune-based
therapies - P.G. Richardson
9.25 a.m. New insights into optimal use of PIs and IMiDs based on
sensitizing targets and biomarkers - P. Moreau
9.40 a.m. Histone deacetilase and kinase inhibitors - S. Lonial
9.55 a.m. Monoclonal antibodies and their integration into the
modern therapeutic algorithms - M. Cavo
1
0.10 a.m. Is personalized therapy ready for primetime? - S.K. Kumar
Other two “interesting issues”
Chairmen: A. Genazzani, P.L. Zinzani
10.30 a.m.
11.00 a.m.
Rituximab biosimilars - P.L. Canonico, M. Peters
The role of liposomal doxorubicin in DLBCL lymphomas - M. Spina
Session VIII: Acute leukemia
Chairmen: S. Amadori, G. Martinelli
11.30 a.m.
11.55 a.m.
6
Status of the art of treatment - H. Dohner
Targeting BET in acute myeloid leukemia - B. Huntly
12.10 p.m.
12.25 p.m.
12.40 p.m.
12.55 p.m.
13.10 p.m.
IDH2 inhibitors in acute myeloid leukemia - E.M. Stein
FLT3 inhibitors in acute myeloid leukemia - R.M. Stone
Inotuzumab ozogamicin in acute lymphoblastic leukemia - H. Kantarjian
BCR-ABL like in acute lymphoblastic leukemia - I. Iacobucci
The role of RO5503781 in acute myeloid leukemia - G. Martinelli
1.30 p.m.
Conclusions and Arrivederci
7
GENERAL INFORMATION
Meeting Venue
Royal Hotel Carlton
Via Montebello, 8 - 40121 Bologna, Italy
Phone +39 051 249361 - Fax +39 051 249724
Official Language
English
Registration Fee
Euro 400,00 (Italian VAT included)
The registration fee includes: Conference kit, partecipation in the scientific sessions, attendance certificate,
coffee breaks, lunch, slides of the meeting.
Badge
All registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted
to the scientific sessions.
Attendance certificate
A certificate will be given to all participants at the end of the meeting.
Italian CME Credits
A request for Italian CME credits have been made as follows:
-Provider Studio ER Congressi SRL: ID 828-155057.
-No. 10 CME credits for physicians (disciplines: Allergology and Clinical Immunology, Dermatology and
Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology),
biologists and chemists.
-Educational objective: “guidelines-protocols-procedures”.
European CME Credits
The program of the “New Drugs in Hematology” has been reviewed and approved for CME accreditation
by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed
by EHA. The EBAH Unit has approved this educational activity for no. 20 CME credits for Physicians,
Biologists and Chemists. To request credits, please fill out the form and return it to the registration desk at
the end of the meeting.
We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees
can create an EBAH-CME account registering on the website: http://ebach.org even on site.
Changes
Parts of the program may be changed without notice.
8
ACKNOWLEDGEMENTS
TM
Scientific Secretariat
Pier Luigi Zinzani
Dipartimento di Ematologia e Scienze
Oncologiche
“Lorenzo e Ariosto Seràgnoli”
Via Massarenti, 9 - 40138 Bologna, Italy
Phone +39 051 6363680 - Fax +39 051 6364037
e-mail: [email protected]
Organizing Secretariat
Studio E.R. Congressi
Via Marconi, 36 - 40122 Bologna, Italy
Phone +39 051 4210559 - Fax +39 051 4210174
e-mail: [email protected]
www.ercongressi.it
struchel.com